Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.79 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29654886 | 1.00 | FFAR4 (0.79) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL8606372 | 1.00 | FFAR4 (0.79) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL31650811 | 1.00 | FFAR4 (0.79) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL29376829 | 1.00 | FFAR4 (0.79) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL5672920 | 1.00 | FFAR4 (0.79) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL5742369 | 1.00 | FFAR4 (0.79) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL15009701 | 1.00 | FFAR4 (0.79) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL4798381 | 1.00 | FFAR4 (0.79) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL22612709 | 1.00 | FFAR4 (0.79) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL29485710 | 1.00 | FFAR4 (0.79) | FFAR4FFAR1LMNATSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | HTR5A, HTR2C, HTR2B | FFAR4 1217/4885FFAR1 1769/4885LMNA 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.